product pipeline  actinium pharmaceuticals inc atnm home product pipeline product pipeline product pipeline candidate  indication development stage r  d preclinical phase  phase  phase  iomabb cd bmt bone marrow transplantpatients over age  with relapsed or refractory amlinduction and conditioning agent prior to a bmt r  d phase complete preclinical phase complete phase  phase complete phase  phase complete phase  phase in progress actimaba fd cd amlnewly diagnosed patientswith aml over age  r  d phase complete preclinical phase complete phase  phase complete phase  phase in progress phase  phase not started actimabm cd multiple myelomarelapsed or refractory patients age  and above r  d phase complete preclinical phase complete phase  phase in progress phase  phase not started phase  phase not started fourth programundisclosed r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started actimabc colon cancer r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started actimabp prostate cancer r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started actimabbr brain cancer r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started bmt or hsct hematopoietic stem cell transplantation is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient email sign up receive the latest news events and updates sign up now actinium pharmaceuticals inc atnm targeted therapies in the fight against cancer actinium is a leading biotechnology company developing targeted radioimmunotherapies for the treatment of cancer patients with unmet needs about actinium the science behind targeted radioimmunotherapy pipeline sierra pivotal phase  clinical trial of iomabb news featured video john pagel md phd discussing iomabb for hsct bone marrow transplant in older patients with relapsedrefractory acute myeloid leukemia tweets by actiniumpharma investor relations investor presentation contact us email sign up receive the latest news events and updates sign up now product pipeline  actinium pharmaceuticals inc atnm home product pipeline product pipeline product pipeline candidate  indication development stage r  d preclinical phase  phase  phase  iomabb cd bmt bone marrow transplantpatients over age  with relapsed or refractory amlinduction and conditioning agent prior to a bmt r  d phase complete preclinical phase complete phase  phase complete phase  phase complete phase  phase in progress actimaba fd cd amlnewly diagnosed patientswith aml over age  r  d phase complete preclinical phase complete phase  phase complete phase  phase in progress phase  phase not started actimabm cd multiple myelomarelapsed or refractory patients age  and above r  d phase complete preclinical phase complete phase  phase in progress phase  phase not started phase  phase not started fourth programundisclosed r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started actimabc colon cancer r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started actimabp prostate cancer r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started actimabbr brain cancer r  d phase complete preclinical phase in progress phase  phase not started phase  phase not started phase  phase not started bmt or hsct hematopoietic stem cell transplantation is a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient email sign up receive the latest news events and updates sign up now investor relations  actinium pharmaceuticals inc atnm home investors investor relations investors investor relations latest news actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et jul   read press release latest financial results q  quarterly results ended mar   pdf html q filing zip xls html xbrl stock information nyse american atnm price change volume market cap  week lowhigh day lowhigh company overview download actinium pharmaceuticals inc wwwactiniumpharmacom is a new yorkbased biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers actiniums targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alphaemitting actinium and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies the companys lead radiopharmaceutical product candidate iomabb is designed to be used upon approval in preparing patients for hematopoietic stem cell transplant hsct commonly referred to as bone marrow transplant bmt the company is conducting a single pivotal multicenter phase  clinical study of iomabb in refractory and relapsed acute myeloid leukemia aml patients over the age of  with a primary endpoint of durable complete remission the companys second product candidate actimaba is continuing its clinical development in a phase  trial for newly diagnosed aml patients over the age of  in a singlearm multicenter trial contact information investor relations actinium pharmaceuticals inc  madison avenue suite  new york ny  investorrelationsactiniumpharmacom transfer agent action stock transfer  e fort union blvd suite  salt lake city ut  t   f   email sign up receive the latest news events and updates sign up now about  actinium pharmaceuticals inc atnm home about about actinium pharmaceuticals inc nyse mktatnm is a publicly traded biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options actiniums proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells both safely and effectively actiniums lead product candidate iomabb is licensed from the fred hutchinson cancer research center and is designed to be used upon approval in preparing patients for a hematopoietic stem cell transplant commonly referred to as bone marrow transplant a bone marrow transplant is often the only potential cure for patients with bloodborne cancers but the current standard preparation for a transplant requires chemotherapy andor total body irradiation that result in significant toxicities we believe iomabb will enable a faster and less toxic preparation of patients seeking a bone marrow transplant leading to increased transplant success and survival rates we are currently conducting a single pivotal patient multicenter phase  clinical study of iomabb in patients with relapsed or refractory acute myeloid leukemia aml age  and older learn more about iomabb and bone marrow transplant for aml here actinium is also developing actimaba our lead alphaparticle drug candidate actimaba is currently in a multicenter openlabel patient phase  trial for patients newly diagnosed with aml age  and over actimaba is being developed to induce remissions in elderly patients with aml who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies learn more about actimaba here in addition actinium has expanded its alphaparticle approach to include newly created drug candidate actimabm which is being studied in patients with relapsed or refractory multiple myeloma in a phase  clinical trial learn more about actimabm and the multiple myeloma trial here actinium is also utilizing its alphaparticle immunotherapy apit technology platform to generate new drug candidates based on antibodies linked to the element actinium that are directed at various bloodborne or solid cancers to learn more about actiniums apit or to explore a potential collaboration using this powerful technology please visit the technology page actinium pharmaceuticals is based in new york ny bone marrow transplant induction and conditioning in one iomabb actinium’s lead asset is in a pivotal phase  clinical trial as an induction and conditioning agent in patients over the age of  with relapsed or refractory acute myeloid leukemia aml prior to receiving a bone marrow transplant bmt also known as a hematopoietic stem cell transplant or hsct view highlights of key opinion leaders discussing iomabb view clinical panel discussion robust pipeline actinium pharmaceuticals drug development pipeline features iomabb which is in a pivotal phase  clinical trial actimaba which is in a phase  clinical trial and actimabm currently in a phase  clinical trial actinium is focused on continuing to expand its drug development pipeline by leveraging its apit technology platform and domain expertise view pipeline email sign up receive the latest news events and updates sign up now contact  actinium pharmaceuticals inc atnm home contact actinium pharmaceuticals inc please contact us for more information actinium pharmaceuticals  madison avenue th floornew york ny  email investorrelationsactiniumpharmacom first name last name email comments submit email sign up receive the latest news events and updates sign up now press releases  actinium pharmaceuticals inc atnm home news  media press releases news  media press releases all news      results  of  actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et jul   actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et jul   actinium pharmaceuticals issues midyear letter to shareholders highlighting accomplishments and significant value enumerating catalysts over the coming quarters jun   actinium pharmaceuticals announces appointment of nitya ray phd as executive vicepresident head of product development manufacturing and supply chain and other key hires in its product development and manufacturing teams jun   actinium pharmaceuticals to host webinar on june th to update on pivotal phase  sierra clinical trial for iomabb jun   actinium pharmaceuticals announces appointment of sandesh seth as chief executive officer jun   actinium pharmaceuticals highlights presence at upcoming society of nuclear medicine and molecular imaging annual meeting jun   update – actinium pharmaceuticals to host webinar on june th to update on pivotal phase  sierra clinical trial for iomabb jun   actinium pharmaceuticals to host webinar on june th to update on pivotal phase  sierra clinical trial for iomabb may   actinium pharmaceuticals granted orphan designation from the european medicines agency for actimaba may              next » email sign up receive the latest news events and updates sign up now actinium pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports actinium pharmaceuticals inc  product pipeline review  actinium pharmaceuticals inc  product pipeline review   wgr  august  global  pages global markets direct description table of content sample report enquiry before buy related reports actinium pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘actinium pharmaceuticals inc  product pipeline review  ’ provides an overview of the actinium pharmaceuticals inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by actinium pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of actinium pharmaceuticals inc  the report provides overview of actinium pharmaceuticals inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses actinium pharmaceuticals inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features actinium pharmaceuticals inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate actinium pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for actinium pharmaceuticals inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding actinium pharmaceuticals inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  actinium pharmaceuticals inc snapshot  actinium pharmaceuticals inc overview  key information  key facts  actinium pharmaceuticals inc  research and development overview  key therapeutic areas  actinium pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  actinium pharmaceuticals inc  pipeline products glance  actinium pharmaceuticals inc  late stage pipeline products  phase iii productscombination treatment modalities  actinium pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  actinium pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  actinium pharmaceuticals inc  drug profiles  iomabb  product description  mechanism of action  rd progress  actimaba  product description  mechanism of action  rd progress  bcy  product description  mechanism of action  rd progress  bcsa  product description  mechanism of action  rd progress  actimabb  product description  mechanism of action  rd progress  actimabbr  product description  mechanism of action  rd progress  actimabc  product description  mechanism of action  rd progress  actimabp  product description  mechanism of action  rd progress  monoclonal antibody conjugate for hematological tumor and oncology  product description  mechanism of action  rd progress  monoclonal antibody conjugate for oncology  product description  mechanism of action  rd progress  actinium pharmaceuticals inc  pipeline analysis  actinium pharmaceuticals inc  pipeline products by target  actinium pharmaceuticals inc  pipeline products by route of administration  actinium pharmaceuticals inc  pipeline products by molecule type  actinium pharmaceuticals inc  pipeline products by mechanism of action  actinium pharmaceuticals inc  recent pipeline updates  actinium pharmaceuticals inc  dormant projects  actinium pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  bismaba  actinium pharmaceuticals inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables actinium pharmaceuticals inc key information  actinium pharmaceuticals inc key facts  actinium pharmaceuticals inc  pipeline by indication   actinium pharmaceuticals inc  pipeline by stage of development   actinium pharmaceuticals inc  monotherapy products in pipeline   actinium pharmaceuticals inc  phase iii   actinium pharmaceuticals inc  phase ii   actinium pharmaceuticals inc  phase i   actinium pharmaceuticals inc  preclinical   actinium pharmaceuticals inc  pipeline by target   actinium pharmaceuticals inc  pipeline by route of administration   actinium pharmaceuticals inc  pipeline by molecule type   actinium pharmaceuticals inc  pipeline products by mechanism of action   actinium pharmaceuticals inc  recent pipeline updates   actinium pharmaceuticals inc  dormant developmental projects  actinium pharmaceuticals inc  discontinued pipeline products   list of figures actinium pharmaceuticals inc  pipeline by top  indication   actinium pharmaceuticals inc  pipeline by stage of development   actinium pharmaceuticals inc  monotherapy products in pipeline   actinium pharmaceuticals inc  pipeline by target   actinium pharmaceuticals inc  pipeline by route of administration   actinium pharmaceuticals inc  pipeline by molecule type   actinium pharmaceuticals inc  pipeline products by mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm united states blood bag tube thermosealers market report  in this report the united states blood bag tube thermosealers market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx betwee united states hemodialysis powder solution market report  in this report the united states hemodialysis powder solution market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx betwee united states hemodialyzer market report  in this report the united states hemodialyzer market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  united states intravenous infusion pump market report  in this report the united states intravenous infusion pump market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  global veterinary vaccine market research report  in this report the global veterinary vaccine market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and   purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports united states blood bag tube thermosealers market report  published  july  united states hemodialysis powder solution market report  published  july  united states hemodialyzer market report  published  july  united states intravenous infusion pump market report  published  july  global veterinary vaccine market research report  published  july  × tell a friend about this report your name your email friends name friends email your enquiry send investor relations  actinium pharmaceuticals inc atnm home investors investor relations investors investor relations latest news actinium pharmaceuticals to host webinar focused on actimaba and recent developments related to cd targeted aml therapies on july   at  am et jul   read press release latest financial results q  quarterly results ended mar   pdf html q filing zip xls html xbrl stock information nyse american atnm price change volume market cap  week lowhigh day lowhigh company overview download actinium pharmaceuticals inc wwwactiniumpharmacom is a new yorkbased biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers actiniums targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alphaemitting actinium and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies the companys lead radiopharmaceutical product candidate iomabb is designed to be used upon approval in preparing patients for hematopoietic stem cell transplant hsct commonly referred to as bone marrow transplant bmt the company is conducting a single pivotal multicenter phase  clinical study of iomabb in refractory and relapsed acute myeloid leukemia aml patients over the age of  with a primary endpoint of durable complete remission the companys second product candidate actimaba is continuing its clinical development in a phase  trial for newly diagnosed aml patients over the age of  in a singlearm multicenter trial contact information investor relations actinium pharmaceuticals inc  madison avenue suite  new york ny  investorrelationsactiniumpharmacom transfer agent action stock transfer  e fort union blvd suite  salt lake city ut  t   f   email sign up receive the latest news events and updates sign up now actinium pharmaceuticals inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report actinium pharmaceuticals inc  product pipeline review   published by global markets direct product code  published august   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license actinium pharmaceuticals inc  product pipeline review   published august   content info  pages description summary global markets directs actinium pharmaceuticals inc  product pipeline review   provides an overview of the actinium pharmaceuticals incs pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by actinium pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope the report provides a snapshot of the pipeline therapeutic landscape of actinium pharmaceuticals inc the report provides overview of actinium pharmaceuticals inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses actinium pharmaceuticals incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features actinium pharmaceuticals incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy evaluate actinium pharmaceuticals incs strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for actinium pharmaceuticals inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding actinium pharmaceuticals incs pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures actinium pharmaceuticals inc snapshot actinium pharmaceuticals inc overview key information key facts actinium pharmaceuticals inc  research and development overview key therapeutic areas actinium pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy actinium pharmaceuticals inc  pipeline products glance actinium pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities actinium pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities actinium pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities actinium pharmaceuticals inc  drug profiles iomabb product description mechanism of action rd progress actimaba product description mechanism of action rd progress bcy product description mechanism of action rd progress bcsa product description mechanism of action rd progress actimabb product description mechanism of action rd progress actimabbr product description mechanism of action rd progress actimabc product description mechanism of action rd progress actimabp product description mechanism of action rd progress monoclonal antibody conjugate for hematological tumor and oncology product description mechanism of action rd progress monoclonal antibody conjugate for oncology product description mechanism of action rd progress actinium pharmaceuticals inc  pipeline analysis actinium pharmaceuticals inc  pipeline products by target actinium pharmaceuticals inc  pipeline products by route of administration actinium pharmaceuticals inc  pipeline products by molecule type actinium pharmaceuticals inc  pipeline products by mechanism of action actinium pharmaceuticals inc  recent pipeline updates actinium pharmaceuticals inc  dormant projects actinium pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles bismaba actinium pharmaceuticals inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables actinium pharmaceuticals inc key information actinium pharmaceuticals inc key facts actinium pharmaceuticals inc  pipeline by indication  actinium pharmaceuticals inc  pipeline by stage of development  actinium pharmaceuticals inc  monotherapy products in pipeline  actinium pharmaceuticals inc  phase iii  actinium pharmaceuticals inc  phase ii  actinium pharmaceuticals inc  phase i  actinium pharmaceuticals inc  preclinical  actinium pharmaceuticals inc  pipeline by target  actinium pharmaceuticals inc  pipeline by route of administration  actinium pharmaceuticals inc  pipeline by molecule type  actinium pharmaceuticals inc  pipeline products by mechanism of action  actinium pharmaceuticals inc  recent pipeline updates  actinium pharmaceuticals inc  dormant developmental projects actinium pharmaceuticals inc  discontinued pipeline products  list of figures actinium pharmaceuticals inc  pipeline by top  indication  actinium pharmaceuticals inc  pipeline by stage of development  actinium pharmaceuticals inc  monotherapy products in pipeline  actinium pharmaceuticals inc  pipeline by target  actinium pharmaceuticals inc  pipeline by route of administration  actinium pharmaceuticals inc  pipeline by molecule type  actinium pharmaceuticals inc  pipeline products by mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved atnm key statistics  actinium pharmaceuticals inc financial ratios  marketwatch bulletin investor alert tokyo markets open in us market snapshot currencies commodities expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close actinium pharmaceuticals inc nyse american atnm go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus actinium pharmaceuticals inc after hours  quotes are delayed by  min jul    pm atnm quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description actinium pharmaceuticals inc operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers it targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alphaemitting actinium  actinium pharmaceuticals inc operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers it targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alphaemitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies its lead radiopharmaceutical iomabb will be used upon approval in preparing patients for hematopoietic stem cell transplant commonly referred to as bone marrow transplant the company was founded in  and is headquartered in new york ny valuation pe current  pe ratio with extraordinary items  price to book ratio  enterprise value to ebitda  efficiency income per employee  liquidity current ratio  quick ratio  cash ratio  profitability return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr sandesh seth   executive chairman  chief executive officer mr steve oloughlin   chief financial  accounting officer dr mark s berger   chief medical officer dr nitya g ray   executive vice president dr maria gomes nunes   managerquality control  assurance insider actions – purchase – sale  – number of transactions  locok loccancel its christmas in july take  off your qualified purchase  get free shipping shop sale     shop sale     its christmas in july take  off yourqualified purchase  get free shipping shop sale       toll free  shopping cart   like us   nutritional supplements all products quality about us contact us   my account about advanced bionutritionals ®about advanced bionutritionals ® advanced bionutritionals is a cutting edge line of nutraceuticals we work closely with our suppliers and our manufacturers to ensure that your supplements are made with fresh quality ingredients following good manufacturing practice guidelines our highly qualified team is always researching new and better ingredients to ensure safe effective health solutions for you frank shallenberger md dr shallenberger has practiced medicine for more than  years after earning his md degree from the university of maryland school of medicine and receiving postgraduate training at mt zion hospital in san francisco dr shallenberger is also certified by the american board of antiaging medicine abaam as an antiaging physician and has also been trained and certified in other areas of alternative medicine this makes dr shallenberger one of a small minority of doctors in this country licensed in conventional as well as alternative medicine but more importantly it allows him to integrate the best of both approaches for optimal results at his wellness clinic the nevada center of alternative and antiaging medicine dr shallenberger has been on the forefront of integrative medicine for several years with his involvement with the american college for the advancement of medicine acam the american preventive medical association and the american academy of antiaging medicine he currently serves as an officer for the orthomolecular medicinehealth society omh founded in honor of twotime nobel prize winner linus pauling dr shallenberger has trained hundreds of physicians on his innovative medical treatments and published numerous scientific papers he is a past clinical instructor of family medicine at the university of californiadavis school of medicine he is also the author of two health books bursting with energy and the type  diabetes breakthrough dr shallenberger also writes the monthly newsletter second opinion shop dr shallenbergers products janet zand omd lac dr janet zand omd lac is a board certified acupuncturist a doctor of oriental medicine a nationally respected author lecturer natural health practitioner and herbal and nutraceutical products formulator who has helped thousands of people achieve better health in magazine describes dr zand as hollywoods best kept health secret because of her alist clientele of movie stars rock stars and professional athletes with over  years of experience in natural medicine she was the cofounder of mczand herbal and the formulator of zand herbal formulas which are sold in natural health stores throughout the country dr zand is also the coauthor of three books on natural health and healing including smart medicine for a healthier child smart medicine for healthier living and the nitric oxide solution she has been featured in elle allure the los angeles times life time tv and the bbc she is the lead formulator for the systeme ® line of allnatural skin care products and edits the popular skin care insider weekly for information about skin care insider visit the website at httpwwwsystemecom she is the editor in chief of womens health letter where each month she brings her readers ways to help them improve their health enjoy their life and thrive shop dr zands supplements steve kroening nd for over  years steve kroening has worked handinhand with some of the nations top doctors including drs frank shallenberger janet zand nan kathryn fuchs william campbell douglass and bestselling author james balch steve is the author of the book practical guide to home remedies as a health journalist steves articles have appeared in countless magazines blogs and websites steve researches breakthrough cures and treatments you wont hear about from mainstream medicine or even other alternative writers he writes in a friendly easytoread style that always gives you the power to guide your own health choices and do more research on your own shop dr kroenings supplements isaac eliaz md ms lac a native of israel dr eliaz received his medical degree from tel aviv university dr eliaz pursued graduate studies in clinical herbology at hebrew university of jerusalem and classical chinese medicine with teachers in israel and europe in  dr eliaz moved to the san francisco bay area in order to continue his studies at the american college of traditional chinese medicine earning a master of science degree in  he currently operates a busy private practice in northern california focusing primarily on integrative holistic protocols as an innovative formulator of dietary supplements dr eliaz developed and currently holds the patents for several of his unique herbal formulations some of these products are available through advanced bionutritionals shop our nutritional supplements free ebook sign up today for free to nutrient insider and be the first to get the latest nutrient breakthroughs you’ll also get immediate access to our ebook “how to make your supplements work even better” submit × free report sign up today for free to nutrient insider and be the first to get the latest nutrient breakthroughs youll also get immediate access to our ebook how to make your supplements work even better advanced bionutritionals® products are manufactured in the usa from globally sourced ingredients by formulation technology inc